Skip to main content

Leadership

2013 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
12/11/13Emergent BioSolutions to Acquire Cangene CorporationDownload PDFPrinter Friendly Version
12/10/13Emergent BioSolutions' Otlertuzumab (TRU-016) Shows Positive Results in Combination with Rituximab in People with CLLDownload PDFPrinter Friendly Version
12/09/13Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab (TRU-016) in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic LeukemiaDownload PDFPrinter Friendly Version
12/02/13Emergent BioSolutions to Webcast Presentation at the 32nd Annual J.P. Morgan Healthcare ConferenceDownload PDFPrinter Friendly Version
11/26/13Emergent BioSolutions Appoints A.B. Cruz III as Executive Vice President and General CounselDownload PDFPrinter Friendly Version
11/20/13Emergent BioSolutions to Webcast Its Participation at the 25th Annual Piper Jaffray Healthcare ConferenceDownload PDFPrinter Friendly Version
11/07/13Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2013Download PDFPrinter Friendly Version
11/07/13Emergent BioSolutions Announces Acceptance of Otlertuzumab Abstracts for Presentation at 2013 American Society of Hematology Annual MeetingDownload PDFPrinter Friendly Version
11/06/13Emergent BioSolutions Presents Preclinical Data on ES414, Its Lead Bispecific ADAPTIR Therapeutic for Prostate CancerDownload PDFPrinter Friendly Version
10/28/13Emergent BioSolutions Wins 2013 North American Maintenance Excellence AwardDownload PDFPrinter Friendly Version
10/15/13Emergent BioSolutions to Webcast Presentation at Credit Suisse 2013 Healthcare ConferenceDownload PDFPrinter Friendly Version
10/07/13Emergent BioSolutions to Release Third Quarter 2013 Financial Results and Conduct a Conference Call on November 7, 2013Download PDFPrinter Friendly Version
08/16/13Emergent BioSolutions Appoints Barry Labinger as Executive Vice President of the Company and President of Its Biosciences DivisionDownload PDFPrinter Friendly Version
08/05/13Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2013Download PDFPrinter Friendly Version
08/02/13Emergent BioSolutions Closes on Its Acquisition of Healthcare Protective Products Division from Bracco Diagnostics Inc.Download PDFPrinter Friendly Version
07/24/13Emergent BioSolutions to Webcast Presentation at Wedbush 2013 Life Sciences Management Access ConferenceDownload PDFPrinter Friendly Version
07/18/13General George A. Joulwan Joins Emergent BioSolutions Board of DirectorsDownload PDFPrinter Friendly Version
07/10/13Emergent BioSolutions Advances Program Supporting Licensure of a Post-Exposure Prophylaxis Indication for BioThraxDownload PDFPrinter Friendly Version
07/08/13Emergent BioSolutions to Release Second Quarter 2013 Financial Results and Conduct a Conference Call on August 5, 2013Download PDFPrinter Friendly Version
07/01/13Emergent BioSolutions Receives Paul-Ehrlich-Institut Approval to Market BioThrax in GermanyDownload PDFPrinter Friendly Version
06/17/13Mayor Virg Bernero Leads Ribbon Cutting of Emergent BioSolutions’ New Administration Building Representing Another Step in Its Lansing Campus ExpansionDownload PDFPrinter Friendly Version
06/17/13Emergent BioSolutions EVP Corporate Affairs Allen Shofe Appointed to MdBio Foundation Board of DirectorsDownload PDFPrinter Friendly Version
06/06/13Emergent BioSolutions to Participate in June and July 2013 Investor ConferencesDownload PDFPrinter Friendly Version
05/20/13Emergent BioSolutions to Webcast Presentation at Jefferies 2013 Global Healthcare ConferenceDownload PDFPrinter Friendly Version
05/16/13Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 23, 2013 at 9:00 AM Eastern; Webcast Will Be AvailableDownload PDFPrinter Friendly Version
05/09/13Emergent BioSolutions to Webcast Presentation at Bank of America Merrill Lynch 2013 Health Care ConferenceDownload PDFPrinter Friendly Version
05/03/13Emergent BioSolutions Presents Preclinical Efficacy Data on ES414 Its Lead ADAPTIR Bispecific Therapeutic for Prostate CancerDownload PDFPrinter Friendly Version
05/02/13Emergent BioSolutions Reports Financial Results for First Quarter 2013Download PDFPrinter Friendly Version
04/30/13Emergent BioSolutions Participates in NATO Defense against Terrorism Workshop at the Counter Terror Expo in LondonDownload PDFPrinter Friendly Version
04/29/13Emergent BioSolutions to Webcast Presentation at Credit Suisse First Annual Antibody DayDownload PDFPrinter Friendly Version
04/25/13Emergent BioSolutions to Acquire Healthcare Protective Products Division of Bracco Diagnostics Inc.Download PDFPrinter Friendly Version
04/11/13Emergent BioSolutions Presents Efficacy Data on ES210; a Bispecific ADAPTIR Molecule for Treating Autoimmune DiseasesDownload PDFPrinter Friendly Version
04/11/13Emergent BioSolutions Announces Positive Preclinical Efficacy and PK Data for Its New Bispecific Adaptir Protein Therapeutic ES414 at AACRDownload PDFPrinter Friendly Version
04/05/13Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and Rituximab Based on Strong Patient Enrollment and Encouraging Early Clinical DataDownload PDFPrinter Friendly Version
04/04/13Emergent BioSolutions to Release First Quarter 2013 Financial Results and Conduct a Conference Call on May 2, 2013Download PDFPrinter Friendly Version
03/07/13Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2012Download PDFPrinter Friendly Version
02/11/13Emergent BioSolutions to Present at Cowen and Company 33rd Annual Health Care ConferenceDownload PDFPrinter Friendly Version
02/04/13Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet Printer Friendly Version
02/01/13Emergent BioSolutions to Release Fourth Quarter and Full Year 2012 Financial Results and Conduct a Conference Call on March 7, 2013Download PDFPrinter Friendly Version
01/22/13Emergent BioSolutions Initiates Phase 2 Study in Pursuit of a Post-Exposure Prophylaxis Indication for BioThraxDownload PDFPrinter Friendly Version
01/17/13Emergent BioSolutions Initiates Phase 2 Clinical Trial for Next Generation Anthrax Vaccine NuThraxDownload PDFPrinter Friendly Version
01/07/13Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013Download PDFPrinter Friendly Version
01/02/13Emergent’s TRU-016 for CLL Receives Orphan Medicinal Product Designation from European CommissionDownload PDFPrinter Friendly Version